Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Nektar Therapeutics Common Stock (NKTR).
- Disclosed ownership: 5%.
- Date of event: 31 Dec 2025.
VANGUARD GROUP INC - 31 Dec 2025 SCHEDULE 13G Report for Nektar Therapeutics Common Stock (NKTR)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Nektar Therapeutics Common Stock
- Symbol
- NKTR
- Shares outstanding
- 20,378,750 shares
- Disclosed Ownership
- 1,027,089 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G
- Filing time
- 30 Jan 2026, 14:20:16 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 31 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5% ownership in Nektar Therapeutics Common Stock (NKTR) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 31 Oct 2025.
- Current filing was accepted on 30 Jan 2026, 14:20.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5% | 1,027,089 | 0 | 143,138 | Ashley Grim | Head of Global Fund Administration |